Minocycline Hydrochloride in Glioblastoma: NCT07735819 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Not yet recruiting
Recruitment status
61
Planned enrollment
2031-06-30
Primary-completion proxy
Executive view
NCT07735819 evaluates Minocycline Hydrochloride in Glioblastoma. The disclosed sponsor is Barbara Ann Karmanos Cancer Institute, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Difference Between Dice Similarity Coefficients (DSC) of Position Emission Tomography (PET) High K Tumor Volume and DSC of MRI-based Tumor Volume (d-PETk-MRI) in Arm 1, assessed over From the time of the pre-radiotherapy scans (Baseline) up to tumor progression or study completion, assessed at a maximum follow-up of 2 years..
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07735819 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Glioblastoma landscape. Drug & Asset MCP drug_fetch was queried for Minocycline Hydrochloride, while Company & Deal Intelligence MCP organization_fetch was queried for Barbara Ann Karmanos Cancer Institute.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07735819 | Minocycline Hydrochloride | Phase 2 / Not yet recruiting | Barbara Ann Karmanos Cancer Institute | United States | Difference Between Dice Similarity Coefficients (DSC) of Position Emission Tomography (PET) High K Tumor Volume and DSC… From the time of the pre-radiotherapy scans (Baseline) up to tumor pr… | 2031-06-30 |
| NCT07811297 | Anlotinib Dihydrochloride | Phase 1/2 / Not yet recruiting | Advenchen Laboratories LLC | United States | Recommended combination dose (RCD) 36 months | 2030-09-01 |
| NCT07758062 | Temozolomide | Phase 2 / Not yet recruiting | Tianjin Medical University General Hospital | China | Progression-Free Survival (PFS) Up to 24 months | 2029-08-01 |
| NCT07754734 | Temozolomide | Phase 2 / Not yet recruiting | Dongguan People's Hospital | Geography not reported | Progression-Free Survival（PFS） From date of randomization until the date of first documented progres… | 2029-07-31 |
| NCT07751744 | JBI-778 | Phase 1/2 / Not yet recruiting | Jubilant Therapeutics, Inc. | Geography not reported | Phase 1 - Incidence of Dose Limiting Toxicities (DLTs) At the end of Cycle 1 (each cycle is 21 days) | 2030-03-31 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07735819 is a Phase 2, not yet recruiting study with 61 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Difference Between Dice Similarity Coefficients (DSC) of Position Emission Tomography (PET) High K Tumor Volume and DSC of MRI-based Tumor Volume (d-PETk-MRI) in Arm 1” over “From the time of the pre-radiotherapy scans (Baseline) up to tumor progression or study completion, assessed at a maximum follow-up of 2 years..” The retrieved endpoint description is: A comparative evaluation of the predictive accuracy of pre-radiotherapy imaging modalities (V1) in forecasting the spatial location of future tumor progression (V2) defined by RANO (Response Assessment in Neuro-Oncology) 2.0 criteria. For each participant, two separate Dice Similarity Coefficients (DSC) will be calculated against the final progression volume (V2): one using the pre-radiotherapy PET High K influx map volume (V1\_PETk) and one using the structural MRI target volume (V1\_MRI). The primary endpoint (d-PETk-MRI) is the absolute difference calculated per patient as DSC\_PETk minus DSC\_MRI. The result….
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 61 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Glioblastoma. These records do not establish direct evidence for NCT07735819 unless the registration number matches.
Phase 1 dose-escalation trial combining sulfasalazine and stereotactic radiosurgery in patients with recurrent glioblastoma
Phase 1; n=12; AE = Of 20 adverse events, two were grade 3 (transient lymphocytopenia), four grade 2, and fourteen grade 1 ; AE = Of 20 adverse events, two were grade 3 (transient lymphocytopenia), four grade 2, and fourteen grade 1 Source: https://pubmed.ncbi.nlm.nih.gov/42229231/
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide i…
Phase 2; n=624; Median Survival Time (Within Center Group)(Median): Cox Proportional Hazard = 0.95(70% CI, 0.81 - 1.10), P-Value = 0.25; Cox Proportional Hazard = 0.81(70% CI, 0.67 - 0.98), P-Value = 0.11; Median Survival Time (Within Center Group)(Median) = 22.8 months (95% Confidence Interval, 20.0 - 28.6) Source: https://clinicaltrials.gov/ct2/show/results/NCT02179086
A First-in-Human Clinical Trial of Pharmacologic Ascorbate and Ferumoxytol Combined With Concomitant Temozolomide and External Beam Radiation Therapy for Newly Diagnosed Glioblast…
Phase 1; n=16; Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs) = 2 Dose Limiting Toxicities ; Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs) = 0 Dose Limiting Toxicities Source: https://clinicaltrials.gov/ct2/show/results/NCT04900792
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Minocycline Hydrochloride is indexed as Small molecule drug with 30S subunit biology and a global stage of Approved. The asset profile lists Pfizer Inc. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Barbara Ann Karmanos Cancer Institute. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Minocycline Hydrochloride is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07735819
Protocol source: https://clinicaltrials.gov/study/NCT07735819
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.
Minocycline Hydrochloride in Glioblastoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Difference Between Dice Similarity Coefficients (DSC) of Position Emission Tomography (PET) High K Tumor Volume and DSC of MRI-based Tumor Volume (d-PETk-MRI) in Arm 1 and 2031-06-30 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
